• Annexon posted a Q2 net loss attributable to common stockholders of USD 55.35 million, or USD 0.28 per share.
• R&D expense rose to USD 46.59 million from USD 44.16 million a year earlier, on Phase 3 ARCHER II and manufacturing costs.
• G&A costs climbed to USD 10.64 million from USD 7.57 million, reflecting higher consulting and professional services.
• Cash, cash equivalents and short-term investments totaled USD 209.2 million at June 30; runway expected to extend into 2028.
• Tanruprubart BLA filing targeted for Q4 2026; vonaprument Month 15 primary endpoint due Q4 2026, Month 24 completion Q3 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Annexon Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608120605PRIMZONEFULLFEED9808504) on August 12, 2026, and is solely responsible for the information contained therein.